Last Updated : April 28, 2024
The latest CADTH Reimbursement Review reports are posted to this page. CADTH reimbursement reviews are comprehensive assessments of the clinical effectiveness and cost-effectiveness, as well as patient and clinician perspectives, of a drug or drug class. The assessments inform non-binding recommendations that help guide the reimbursement decisions of Canada's federal, provincial, and territorial governments, with the exception of Quebec. Implementation advice and funding algorithms are provided where applicable.
| Brand Name | Generic Name | Therapeutic Area | Recommendation Type | Project Status | Date Submission Received Sort ascending | Date Recommendation Issued |
|---|---|---|---|---|---|---|
| Exjade | Deferasirox | Iron overload | List with clinical criteria and/or conditions | Complete | ||
| Tysabri | Natalizumab | Multiple Sclerosis, relapsing-remitting | Do not list | Complete | ||
| Altace HCT | Ramipril/hydrochlorothiazide | Hypertension | Cancelled | |||
| Orencia | Abatacept | Arthritis, Rheumatoid | List with clinical criteria and/or conditions | Complete | ||
| Myozyme | Alglucosidase | Pompe's disease | List with clinical criteria and/or conditions | Complete | ||
| Tramacet | Tramadol hydrochloride /acetaminophen | Acute pain | Do not list | Complete | ||
| Strattera | Atomoxetine hydrochloride | Attention deficit hyperactivity disorder | N/A | Complete | ||
| Denavir | Penciclovir | Herpes labialis (cold sores) | Do not list | Complete | ||
| Revatio | Sildenafil citrate | Pulmonary arterial hypertension (WHO class II and III) | List in a similar manner | Complete | ||
| Sutent | Sunitinib malate | Cancer, Metastatic renal cell carcinoma | Do not list | Complete |
Last Updated : April 28, 2024